Lite Strategy, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Lite Strategy, Inc. (LITS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $270.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-05-13
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $270.00K, a 1587.50% increase year-over-year.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $234.00K.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $284.00K.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $16.00K, a 97.60% decline year-over-year.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was -$144.00K, a 106.32% decline from fiscal 2024.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.28M, a 36.53% decline from fiscal 2023.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.59M, a 57.02% decline from fiscal 2022.
- Lite Strategy, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.35M, a 18.50% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-03-31 | $270.00K 10-Q · filed 2026-05-13 | $504.00K derived: sum of 2 quarters · filed 2026-05-13 | $788.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2025-12-31 | $234.00K 10-Q · filed 2026-05-13 | $518.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2025-09-30 | $284.00K 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | -$144.00K 10-K · filed 2025-09-26 | |||
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-13 | -$87.00K derived: sum of 2 quarters · filed 2026-05-13 | -$222.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$103.00K 10-Q · filed 2026-05-13 | -$238.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-09-30 | -$135.00K 10-Q · filed 2026-05-13 | |||
| 2024-06-30 | $2.28M 10-K · filed 2025-09-26 | |||
| 2024-03-31 | $668.00K 10-Q · filed 2025-05-13 | $1.52M derived: sum of 2 quarters · filed 2025-05-13 | $1.88M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $850.00K 10-Q · filed 2025-05-13 | $1.21M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-09-30 | $363.00K 10-Q · filed 2025-05-13 | |||
| 2023-06-30 | $3.59M 10-K · filed 2024-09-19 | |||
| 2023-03-31 | $918.00K 10-Q · filed 2024-05-09 | $1.73M derived: sum of 2 quarters · filed 2024-05-09 | $3.29M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $813.00K 10-Q · filed 2024-05-09 | $2.37M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-09-30 | $1.56M 10-Q · filed 2024-05-09 | |||
| 2022-06-30 | $8.35M 10-K · filed 2023-09-26 | |||
| 2022-03-31 | $2.84M 10-Q · filed 2023-05-11 | $5.16M derived: sum of 2 quarters · filed 2023-05-11 | $7.70M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $2.32M 10-Q · filed 2023-05-11 | $4.86M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-09-30 | $2.54M 10-Q · filed 2023-05-11 | |||
| 2021-06-30 | $10.24M 10-K · filed 2022-09-08 | |||
| 2021-03-31 | $2.65M 10-Q · filed 2022-05-23 | $5.25M derived: sum of 2 quarters · filed 2022-05-23 | $8.20M derived: sum of 3 quarters · filed 2022-05-23 | |
| 2020-12-31 | $2.61M 10-Q/A · filed 2022-05-23 | $5.55M derived: sum of 2 quarters · filed 2022-05-23 | ||
| 2020-09-30 | $2.94M 10-Q/A · filed 2022-05-23 | |||
| 2020-06-30 | $6.80M 10-K · filed 2022-09-08 | |||
| 2020-03-31 | $1.55M 10-Q · filed 2021-05-06 | $3.32M derived: sum of 2 quarters · filed 2021-05-06 | $5.43M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $1.77M 10-Q · filed 2021-05-06 | $3.88M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-09-30 | $2.11M 10-Q · filed 2021-05-06 | |||
| 2019-06-30 | $6.56M 10-K/A · filed 2022-05-23 | |||
| 2019-03-31 | $1.51M 10-Q · filed 2020-05-07 | $3.18M derived: sum of 2 quarters · filed 2020-05-07 | $5.11M derived: sum of 3 quarters · filed 2020-05-07 | |
| 2018-12-31 | $1.66M 10-Q · filed 2020-05-07 | $3.60M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-09-30 | $1.94M 10-Q · filed 2020-05-07 | |||
| 2018-06-30 | $3.22M 10-K · filed 2020-09-09 | |||
| 2018-03-31 | $770.00K 10-Q · filed 2019-05-09 | $1.47M derived: sum of 2 quarters · filed 2019-05-09 | $2.47M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $702.00K 10-Q · filed 2019-05-09 | $1.70M derived: sum of 2 quarters · filed 2019-05-09 | ||
| 2017-09-30 | $996.00K 10-Q · filed 2019-05-09 | |||
| 2017-06-30 | $2.30M 10-K · filed 2019-08-28 | |||
| 2016-06-30 | $2.72M 10-K · filed 2018-08-30 | |||
| 2015-06-30 | $4.22M 10-K · filed 2017-09-05 | |||
| 2014-06-30 | $4.75M 10-K · filed 2016-09-06 | |||
| 2013-06-30 | $1.51M 10-K · filed 2015-09-02 | |||
| 2012-06-30 | $511.00K 10-K · filed 2014-09-09 | |||
| 2011-06-30 | $484.00K 10-K · filed 2013-09-18 | |||
| 2010-06-30 | $64.00K 10-K · filed 2013-09-18 | |||
| 2009-06-30 | $90.00K 10-K · filed 2013-09-18 | |||
| 2008-06-30 | $441.00K 10-K · filed 2013-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |